ACTU
1:00 PM
2026-ASCO-Post-hoc efficacy and biomarker analysis of elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy alone in metastatic pancreatic ductal adenocarcinoma
Presentation / Abstractactuatetherapeutics.com
Catalyst Calendar
Sat, May 30, 2026
2 updatesACTU
1:00 PM
2026-ASCO-A phase II study of FOLFIRINOX (FFX) combined with the glycogen synthase kinase-3beta (GSK-3β) inhibitor elraglusib (ELRA) and the transforming growth factor beta (TGFβ) inhibitor losartan (LOS) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
Presentation / Abstract • Phase 2ASCO abstract release Mon, Jun 1, 2026actuatetherapeutics.com
Tue, Apr 14, 2026
1 updatesACTU
8:00 AM